Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis.
Several immune-based approaches are being considered for modulation of inflammatory T cells and amelioration of autoimmune diseases. The most recent strategies include simulation of peripheral self-tolerance by injection of adjuvant free antigen, local delivery of cytokines by genetically altered T cells, and interference with the function of costimulatory molecules. Although promising results have been obtained from these studies that define mechanisms of T cell modulation, efficacy, practicality, and toxicity, concerns remain unsolved, thereby justifying further investigations to define alternatives for effective downregulation of aggressive T cells. In prior studies, we demonstrated that an immunoglobulin (Ig) chimera carrying the encephalitogenic proteolipid protein (PLP)1 peptide corresponding to amino acid sequence 139-151 of PLP, Ig-PLP1, is presented to T cells approximately 100-fold better than free PLP1. Here, we demonstrate that aggregation endows Ig-PLP1 with an additional feature, namely, induction of interleukin (IL)-10 production by macrophages and dendritic cells, both of which are antigen-presenting cells (APCs). These functions synergize in vivo and drive effective modulation of autoimmunity. Indeed, it is shown that animals with ongoing active experimental allergic encephalomyelitis dramatically reduce the severity of their paralysis when treated with adjuvant free aggregated Ig-PLP1. Moreover, IL-10 displays bystander antagonism on unrelated autoreactive T cells, allowing for reversal of disease involving multiple epitopes. Therefore, aggregated Ig-PLP1 likely brings together a peripheral T cell tolerance mechanism emanating from peptide presentation by APCs expressing suboptimal costimulatory molecules and IL-10 bystander suppression to drive a dual-modal T cell modulation system effective for reversal of autoimmunity involving several epitopes and diverse T cell specificities.
Legge
K L
KL
Department of Microbiology, University of Tennessee, Knoxville, Tennessee 37996, USA.
Min
B
B
Bell
J J
JJ
Caprio
J C
JC
Li
L
L
Gregg
R K
RK
Zaghouani
H
H
D000818:Animals; D000936:Antigen-Antibody Complex / Q000627:therapeutic use; D000938:Antigen-Presenting Cells / Q000276:immunology; D015536:Down-Regulation; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000628:therapy*; D000939:Epitopes; D007108:Immune Tolerance; D007167:Immunotherapy; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis*; D008074:Lipoproteins / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008565:Membrane Proteins / Q000627:therapeutic use*; D051379:Mice; D018991:Myelin Proteolipid Protein; D009186:Myelin Sheath / Q000276:immunology*; D010243:Paralysis / Q000628:therapy; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology*
D000936:Antigen-Antibody Complex; D000939:Epitopes; D008074:Lipoproteins; D008565:Membrane Proteins; D018991:Myelin Proteolipid Protein; C472930:PLP1 protein, human; D016753:Interleukin-10; D007371:Interferon-gamma